Isatuximab, CAS 1461640-62-9

Product Description: Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23;:]. Drugs. 2020;80(9):905-912./[2]Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394(10214):2072]. Lancet. 2019;394(10214):2096-2107.

CAS Number: 1461640-62-9

Molecular Weight: N/A

Compound Purity: 98.5

Research Area: Cancer

Solubility: H2O

Target: Apoptosis

• Artikelnummer: MEXHY-P9976-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9976-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated